The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials. Sundquist’s research focuses on ...

Science also stresses that lenacapavir becoming a key drug to accelerate HIV prevention largely depends on access to the drug. "The price, which has not yet been set, will determine who can afford ...

The 2024 breakthrough of the year, according to the journal Science, was with the drug lenacapavir, an antiretroviral medicine that performed very well in scientific trials. Dr. Robert Hopkins Jr ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking clinical trial results for a drug called lenacapavir showed it to be ...

As its 2024 Breakthrough of The Year, Science has named the development of lenacapavir – a promising new injectable drug that prevents HIV infection. The award also recognizes related work ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science magazine's "Breakthrough of the Year" jury announced on Thursday.

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a once-yearly injectable formulation for lenacapavir. The annual formulation is ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that prevents infection... Can we eliminate the HIV epidemic? It's a ...